IDiyas

For the Inventor, By the Inventor

Ijamsville, MD, United States of America

Michael R Boyd

USPTO Granted Patents = 56



Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 175(Granted Patents)

Forward Citations (Not Self Cited) = 133(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Ijamaville, MD (US) (2002)
  • Ijamsville, MD (US) (1994 - 2008)
  • Mobile, AL (US) (2006 - 2017)

Company Filing History:

goldMedal30 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
silverMedal15 out of 1,215 
 
The United States of America As Represented by the Department of Health
 patents
bronzeMedal5 out of 2,202 
 
The United States of America As Represented by the Secretary of
 patents
4. 2 out of 16,070 
 
USA As Represented by Secretary of the Navy
 patents
5. 2 out of 13 
 
The United States of America As Represented by the Secretary, Department
 patents
6. 2 out of 45 
 
Nektar Therapeutics Al, Corporation
 patents
7. 2 out of 2,340 
 
University of Illinois
 patents
8. 2 out of 111 
 
The Trustees of Boston College
 patents
9. 1 out of 470 
 
Brigham Young University
 patents
10. 1 out of 1 
 
National Institute of Heatlh
 patent
11. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1994-2017

Loading Chart...
Loading Chart...
Loading Chart...
56 patents (USPTO):Explore Patents
1. 9820965 - Biologically active macrolides, compositions, and uses thereof (2017-11-21),
2. 9139595 - Biologically active macrolides, compositions, and uses thereof (2015-09-22),
3. 8741947 - Biologically active macrolides, compositions, and uses thereof (2014-06-03),
4. 8609716 - Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof (2013-12-17),
5. 8394764 - Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use (2013-03-12),
6. 8278348 - Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof (2012-10-02),
7. 7884178 - Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use (2011-02-08),
8. 7790764 - Biologically active macrolides, compositions, and uses thereof (2010-09-07),
9. 7754420 - Methods of using cyanovirins to inhibit viral infection (2010-07-13),
10. 7547509 - Cyanovirin variant-polymer conjugates (2009-06-16),
11. 7521475 - Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof (2009-04-21),
12. 7491798 - Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins (2009-02-17),
13. 7381744 - Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds (2008-06-03),
14. 7339037 - Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins (2008-03-04),
15. 7267941 - Cyanovirin variant-polymer conjugates (2007-09-11),

Title: Innovator Spotlight: Michael R Boyd - Pioneering Biologically Active Macrolides

Introduction:

Michael R Boyd, a distinguished inventor hailing from Ijamsville, MD, has made remarkable contributions to the field of pharmaceuticals through his pioneering work in biologically active macrolides. With an impressive portfolio of 56 patents, Boyd has cemented his legacy as a trailblazer in the realm of medicinal chemistry and drug development.

Latest Patents:

Boyd's latest patents revolve around biologically active macrolides, compositions, and their diverse therapeutic applications. His innovative compounds, characterized by intricate molecular structures denoted by formulas (I) and (II), showcase his prowess in designing novel molecules with potent pharmacological activities. These compounds have shown promising results in treating conditions that are responsive to the inhibition of vacuolar-type (H+)-ATPase, including cancer.

Career Highlights:

Throughout his illustrious career, Boyd has been associated with esteemed organizations such as The United States of America As Represented by the Department of Health and Human Services and The United States of America As Represented by the Department of Health. His strategic insights and scientific acumen have propelled groundbreaking research initiatives, paving the way for the development of innovative pharmaceutical formulations.

Collaborations:

Boyd's collaborative efforts have been instrumental in driving scientific advancements in the field of medicinal chemistry. Working alongside accomplished colleagues like Kirk R Gustafson and James Brislin McMahon, Boyd has fostered a culture of innovation and excellence, leading to the successful translation of cutting-edge research into tangible therapeutic solutions.

Conclusion:

In conclusion, Michael R Boyd stands out as a visionary inventor who continues to push the boundaries of pharmaceutical innovation. His multidisciplinary approach, coupled with a relentless commitment to scientific excellence, underscores his status as a key figure in the realm of biologically active macrolides. Boyd's remarkable contributions serve as a testament to his unwavering dedication to improving healthcare outcomes through transformative inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…